In vivo pharmacodynamic target investigation of two bacterial topoisomerase inhibitors, ACT-387042 and ACT-292706, in the neutropenic murine thigh model against Streptococcus pneumoniae and Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3626-3632

  Lepak, A J ^a   Seiler, P ^b   Surivet, J P ^b   Ritz, D ^b   Kohl, C ^b   Andes, D R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 292706; ACT 387042; ANTIINFECTIVE AGENT; BETA LACTAM; CIPROFLOXACIN; DNA TOPOISOMERASE INHIBITOR; METICILLIN; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; ACT-292706; ACT-387042; NAPHTHYRIDINE DERIVATIVE; PYRAN DERIVATIVE; PYRIDAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THIGH INFECTION; ANIMAL; BLOOD; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; INSTITUTE FOR CANCER RESEARCH MOUSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOLOGY; PNEUMOCOCCAL INFECTIONS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; SUBCUTANEOUS DRUG ADMINISTRATION; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; INJECTIONS, SUBCUTANEOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; NEUTROPENIA; PNEUMOCOCCAL INFECTIONS; PYRANS; PYRIDAZINES; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; THIGH; TOPOISOMERASE INHIBITORS;

EID: 84973532150     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00363-16     Document Type: Article

References (22)

1. Surivet JP, Zumbrunn C, Rueedi G, Bur D, Bruyere T, Locher H, Ritz D, Seiler P, Kohl C, Ertel EA, Hess P, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Kraemer S, Gaertner M, Delers J, Enderlin-Paput M, Weiss M, Sube R, Hadana H, Keck W, Hubschwerlen C. 2015. Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile. J Med Chem 58:927-942. http://dx.doi.org/10.1021/jm501590q.
2. Ehmann DE, Lahiri SD. 2014. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase. Curr Opin Pharmacol 18:76-83. http://dx.doi.org/10.1016/j.coph.2014.09.007.
3. Surivet JP, Zumbrunn C, Rueedi G, Hubschwerlen C, Bur D, Bruyere T, Locher H, Ritz D, Keck W, Seiler P, Kohl C, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Gaertner M, Delers J, Enderlin-Paput M, Boehme M. 2013. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity. J Med Chem 56:7396-7415. http://dx.doi.org/10.1021/jm400963y.
4. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940. http://dx.doi.org/10.1038/nature09197.
5. Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C. 2008. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 52:3339-3349. http://dx.doi.org/10.1128/AAC.00496-08.
6. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
7. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
8. Andes D, Craig WA. 1998. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am 12:849-860. http://dx.doi.org/10.1016/S0891-5520(05)70024-6.
9. Andes D, Craig WA. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 46:1665-1670. http://dx.doi.org/10.1128/AAC.46.6.1665-1670.2002.
10. Andes D, Craig WA. 2003. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother 47:3935-3941. http://dx.doi.org/10.1128/AAC.47.12.3935-3941.2003.
11. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073-1081. http://dx.doi.org/10.1128/AAC.37.5.1073.
12. Tam VH, Chang KT, Yang Z, Newman J, Hu M. 2013. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother 57:1062-1064. http://dx.doi.org/10.1128/AAC.01208-12.
13. Bulik CC, Okusanya OO, Bhavnani SM, Lepak A, Forrest A, Ambrose PG, Hoover JL, Andes DR. 2014. Evaluation of the pharmacokinetics-pharmacodynamics (PK-PD) of GSK2140944 against Staphylococcus aureus and Streptococcus pneumoniae in a murine thigh-infection model, poster A-680. Abstr 54th Intersci Conf Antimicrob Agents Chemother, Washington, DC.
14. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10, quiz 11-12. http://dx.doi.org/10.1086/516284.
15. Blaser J, Stone BB, Groner MC, Zinner SH. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054-1060. http://dx.doi.org/10.1128/AAC.31.7.1054.
16. Craig W, Dalhoff A. 1998. Pharmacodynamics of fluoroquinolones in experimental animals, p 208-232. In Kuhlman J, Dalhoff A, Zeiller HJ (ed), Handbook of experimental pharmacology, vol 127. Springer-Verlag, Berlin, Germany.
17. Lister PD, Sanders CC. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43:79-86. http://dx.doi.org/10.1093/jac/43.1.79.
18. Lister PD, Sanders CC. 1999. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 43:1118-1123.
19. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831-847. http://dx.doi.org/10.1093/infdis/158.4.831.
20. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE. 2014. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against Gramnegative bacteria and in vivo efficacy. Antimicrob Agents Chemother 58:2657-2664. http://dx.doi.org/10.1128/AAC.02778-13.
21. Lepak A, Seiler P, Surivet JP, Ritz D, Kohl C, Andes D. 2015. Pharmacokinetic/pharmacodynamic evaluation of a novel topo-isomerase inhibitor, ACT-292706, in a murine thigh and lung infection model against Staphylococcus aureus and Streptococcus pneumoniae, abstr A-047. Abstr 55th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
22. Lepak A, Seiler P, Surivet JP, Ritz D, Kohl C, Andes D. 2015. Pharmacokinetic/pharmacodynamic evaluation of a novel topo-isomerase inhibitor, ACT-387042, in a murine thigh and lung infection model against Staphylococcus aureus (SA) and Streptococcus pneumoniae (SPN) abstr A-046. Abstr 55th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.